Subscribe To
Moderna (mrna), merck's cancer jab delays melanoma recurrence
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine cand...
April 17, 2023, 12:56 pm
Moderna shares fall despite promising data from cancer vaccine trial
Moderna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treatin...
April 17, 2023, 11:30 am
Gritstone bio presents 6-month neutralizing antibody (nab) data at eccmid 2023 from two phase 1 studies evaluating self-amplifying mrna (samrna) against sars-cov-2 (coral)
— CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses ...
April 17, 2023, 11:01 am
Moderna (mrna) stock sinks despite positive cancer vaccine update
Moderna (NASDAQ: MRNA ) stock is sinking this morning despite releasing positive data about its cancer vaccin<...
April 17, 2023, 10:00 am
This prediction may completely change your opinion of moderna
Investors have worried about declining coronavirus vaccine revenue at Moderna. The company has many pot...
April 17, 2023, 5:30 am
Wall street analysts are bullish on moderna stock price: should you?
Moderna (NASDAQ: MRNA) stock price will be in the spotlight on Monday after the company announced important outcome of its skin cancer v...
April 17, 2023, 3:55 am
: moderna, merck combo cancer-vaccine treatment shows ‘significant’ promise
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study...
April 16, 2023, 9:21 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin<...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin<...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin<...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin<...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin<...
April 16, 2023, 9:00 pm
Moderna, merck combo cancer-vaccine treatment shows ‘significant' promise
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study...
April 16, 2023, 5:21 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm